Superworth

Ultragenyx Pharmaceutical price to book ratio RARE

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
22.0×
Oct 2025
10-year median
6.4×
10-year range
2.9× to 127×
Peer median
2.8×

Ultragenyx Pharmaceutical's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Oct 2025, at 22.0×.

On the days it had one over the last ten years, its median was 6.4×, from 2.9× in Nov 2019 to 127× in Feb 2024.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202522.0×10.7×26.2×
202411.6×10.7×127×
2023124×6.3×124×
20226.9×3.8×6.9×
20216.1×5.1×14.9×
202012.7×3.3×15.8×
20193.4×2.9×6.3×
20183.2×3.0×7.1×
20175.4×4.6×7.8×
20166.3×3.6×7.8×
20157.6×6.3×15.7×
20147.1×6.2×12.0×

Against its peers

Companies in Drug Manufacturers - General nearest Ultragenyx Pharmaceutical's size, closest first, today.

CompanyPrice to book ratio
RAREUltragenyx Pharmaceuticaln/m
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
PCRXPacira BioSciences2.2×
ANIPANI Pharmaceuticals2.8×
OMEROmerosn/m
HRMYHarmony Biosciences2.1×
AMPHAmphastar Pharmaceuticals1.4×
PBHPrestige Consumer Healthcare1.2×
NRIXNurix Therapeutics2.9×
ABUSArbutus Biopharma3.2×
Peer median2.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Ultragenyx Pharmaceutical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.